Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rezolute, Inc. (Nasdaq: RZLT) SEC filings page provides access to the company’s regulatory disclosures as a publicly traded, late-stage rare disease company focused on hypoglycemia caused by hyperinsulinism. Through these documents, investors can review how Rezolute reports on its clinical programs, financial condition, governance and shareholder matters.
Current reports on Form 8-K include items such as clinical and business updates, financial results, and corporate actions. For example, recent 8-K filings reference press releases on quarterly and annual financial results, alignment with the U.S. Food and Drug Administration on the design of the Phase 3 upLIFT study in tumor hyperinsulinism, and updates on the ersodetug development program. Other 8-Ks describe material agreements, executive appointments, amendments to employment arrangements, and the termination of an at-the-market equity program.
Proxy materials, such as the definitive proxy statement on Schedule DEF 14A, outline proposals presented at Rezolute’s annual meeting of stockholders. These include the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, amendments to the company’s equity incentive plan, and potential adjournment proposals. Related 8-K filings report the final voting results for these matters.
Investors can also use this page to locate filings that incorporate press releases on financial results, which provide additional context on research and development spending, general and administrative expenses, and net loss figures, as described by the company. While this page focuses on accessing the underlying SEC documents, AI-powered tools on the platform can help summarize key points from lengthy filings, highlight important sections, and make it easier to understand Rezolute’s disclosures on clinical progress, compensation policies and capital structure.
Together, these SEC filings form an official record of Rezolute’s activities as a Nasdaq-listed issuer developing its lead monoclonal antibody therapy, ersodetug, for congenital and tumor hyperinsulinism.
Insider Trading Alert: Brian Kenneth Roberts, Chief Medical Officer of Rezolute (RZLT), has acquired 2,500 common shares at a weighted average price of $4.3756 per share on June 25, 2025. The transaction was executed through multiple purchases ranging from $4.37 to $4.38 per share.
Following this transaction, Roberts' holdings include:
- Direct ownership: 172,852 common shares (15,500 + 157,352 from previous holdings)
- Indirect ownership: 1,376 shares held by minor child
This insider purchase demonstrates continued confidence in the company by a key executive. The Form 4 filing was completed within the required reporting timeframe, with the transaction executed on June 25, 2025, and reported on June 28, 2025.
Filing overview: On 24 June 2025, Rezolute, Inc. (ticker RZLT) submitted a Form 4 disclosing a change in beneficial ownership by its Chief Financial Officer, Daron Evans.
Transaction details: Mr. Evans executed an open-market purchase (transaction code “P”) of 5,000 common shares at $4.05 per share on the reported date. No sales or other derivative transactions were listed.
Post-transaction holdings: After the purchase, the CFO directly holds 268,900 shares. He also reports indirect ownership of 23,000 shares for minor child #1, 20,000 shares held by his spouse, 4,500 shares each for minor children #2 and #3, and 40,000 shares through PoC Capital LLC, a California entity he manages. Combined, these positions represent 360,900 common shares. The filing states that Evans disclaims beneficial ownership of PoC Capital shares except for his pecuniary interest.
The Form 4 was electronically signed by Daron Evans on 24 June 2025.
Form 4 overview: Rezolute, Inc. (RZLT) disclosed that director Young-Jin Kim executed a substantial open-market purchase of the company’s common stock on 13 June 2025.
- Transaction code P (Purchase): 1,230,769 common shares acquired indirectly through Handok, Inc. at $3.25 per share, implying a cash outlay of roughly $4.0 million.
- Post-transaction holdings: Handok, Inc. now holds 8,423,386 shares (indirect ownership attributed to Kim). Kim also continues to hold 149,950 shares directly; no change was reported for the direct position.
- The filing states that Kim “disclaims beneficial ownership” of Handok’s holdings except to the extent of any pecuniary interest, but SEC rules still require attribution because he is a director of Rezolute and a control person at Handok.
Investment take-aways:
- A multi-million-dollar insider purchase often signals personal or strategic confidence in Rezolute’s pipeline and valuation.
- The purchase increases Handok’s stake and may strengthen the strategic relationship between the two companies, as Handok has historically been a significant investor and commercial partner.
- No derivative transactions, sales, or option exercises were reported, underscoring a purely additive position.
The Form 4 contains no earnings metrics, operational updates or forward-looking statements; the filing is limited to reporting the insider trade required under Section 16(a).
Rezolute, Inc. (RZLT) – Form 4 insider transaction
Director Nerissa Kreher reported purchasing 3,076 common shares of Rezolute on 13 June 2025 at an average price of $3.25 per share. Following the transaction, Dr. Kreher directly owns 37,576 shares of the company’s common stock. No derivative securities were involved, and no dispositions were reported.